Sign Out
Epoetin beta (Recormon) is indicated for: Treatment of symptomatic anemia associated with chronic kidney disease (CKD) in patients on dialysis.
Treatment of symptomatic renal anemia in patients not yet undergoing dialysis.
Prevention of anemia of prematurity in infants with a birth weight of 750 to 1500 g and a gestational age of less than 34 weeks.
Treatment of symptomatic anemia in adult patients with non-myeloid malignancies receiving chemotherapy.
Increasing the yield of autologous blood from patients in a pre-donation program. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anemia (Hb 10-13 g/dl [6.21-8.07 mmol/L], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).
Continue with Google